TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7840258

Group type: EXPERIMENTAL
Intervention: Capillary pressure measurement in women
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Capillary pressure measurement in men
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Capillary pulse pressure amplitude related to skin temperature in women
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Time taken for systolic pressure rise to reach capillary in women
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: High-frequency waves in pressure waveform related to age
Number of subjects: 74
Study: 2195528

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (50 ng kg‐1 min‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (Normal saline)
Number of subjects: 16
Study: 721343

Group type: EXPERIMENTAL
Intervention: Methadone patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonaddict control group
Number of subjects: 0
Study: 31789786

Group type: EXPERIMENTAL
Intervention: Crowdsourced lay observers
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Professional graders from DIRC
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Oculoplastic experts
Number of subjects: 205

Group type: COMPARATOR
Intervention: Lay observers
Number of subjects: 205

Group type: COMPARATOR
Intervention: DIRC graders
Number of subjects: 205
Study: 31190735

Group type: EXPERIMENTAL
Intervention: Anifrolumab (fully human monoclonal antibody targeting IFNAR1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anifrolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27834474

Group type: EXPERIMENTAL
Intervention: Mepivacaine 2%
Number of subjects: 18
Study: 25483366

Group type: EXPERIMENTAL
Intervention: Calcifediol (140 μg weekly)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cholecalciferol (140 μg weekly)
Number of subjects: 57
Study: 21932396

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control group (half-day psycho-educational seminar)
Number of subjects: 257
Study: 21831348

Group type: EXPERIMENTAL
Intervention: Dentifrice with 5000ppm fluoride
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control dentifrice with 1450ppm fluoride
Number of subjects: 16
Study: 19771283

Group type: EXPERIMENTAL
Intervention: ECC isotonic exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: CON-ECC isokinetic exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 17893310

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 4573

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4573
Study: 15564936

Group type: EXPERIMENTAL
Intervention: Sevoflurane-pancuronium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl-midazolam-pancuronium
Number of subjects: 30
Study: 11726266

Group type: EXPERIMENTAL
Intervention: Overhydrated (OH)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Euhydrated (EUH)
Number of subjects: 11
Study: 9409369

Group type: EXPERIMENTAL
Intervention: Self-reported dependency assessment
Number of subjects: 0
Study: 8287583

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b (IFN) therapy for 24 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 68
Study: 3566601

Group type: EXPERIMENTAL
Intervention: 2% pilocarpine nitrate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control eye (no treatment)
Number of subjects: 23
Study: 31062999

Group type: EXPERIMENTAL
Intervention: Multiple Wingate All‐Out Performance Test (WG)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 32
Study: 28141897

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) with low-dose tacrolimus (LTac) and prednisone
Number of subjects: 309
Study: 25721183

Group type: EXPERIMENTAL
Intervention: Sertraline (SRT, n = 133)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT, n = 139)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Combination of both (COMB, n = 140)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Pill Placebo (PBO, n = 76)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 488
Study: 23937345

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) augmentation of cognitive behavioral therapy (CBT)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo augmentation of cognitive behavioral therapy (CBT)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 169
Study: 21521468

Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (NM) 0.02 mg/kg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 62
Study: 18046527

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2022

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2022
Study: 16925689

Group type: EXPERIMENTAL
Intervention: Tolerant patients (n = 29)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Clinically reactive non-IgE-mediated CMA patients (n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: IgE-mediated CMA patients (n = 19)
Number of subjects: 29
Study: 14536040

Group type: EXPERIMENTAL
Intervention: Prototype Mk IV implant (test)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Brånemark implant (control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both test and control implants
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Test implants
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control implants
Number of subjects: 44
Study: 10936478

Group type: EXPERIMENTAL
Intervention: Third-generation thrombolytic agents (monteplase, tenecteplase, reteplase, lanoteplase, pamiteplase, staphylokinase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second-generation agent (alteplase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third-generation thrombolytic agents
Number of subjects: 0
Study: 8656336

Group type: EXPERIMENTAL
Intervention: Self-report measures (locus-of-control scale)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Content engagement process (Study 2)
Number of subjects: 480
Study: 1727274

Group type: EXPERIMENTAL
Intervention: MR imaging at 0.5 T
Number of subjects: 11

Group type: COMPARATOR
Intervention: CT imaging
Number of subjects: 11

Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MR imaging compared to CT
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MR imaging compared to chest radiography
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Short inversion time inversion-recovery sequences
Number of subjects: 11
Study: 6837243

Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg body weight
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 19
Study: 31652166

Group type: EXPERIMENTAL
Intervention: 2 mg/d of brexpiprazole
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: 4 mg/d of brexpiprazole
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1094
Study: 30014662

Group type: EXPERIMENTAL
Intervention: Medication plus rehabilitation training plus acupuncture (observation 2 group)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Medication plus rehabilitation training (observation 1 group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Medication alone (control group)
Number of subjects: 78
Study: 25689448

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1,600 mg
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1,200 mg
Number of subjects: 193

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 193
Study: 23637031

Group type: EXPERIMENTAL
Intervention: Ansell Perry Orthopaedic (thickest glove)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-sterile glove
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Latex-free, powder-free (Cardinal Esteem)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Latex powder-free (Mölnlycke-Biogel)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All glove types
Number of subjects: 42
Study: 22029225

Group type: EXPERIMENTAL
Intervention: Esomeprazole formulation 1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Esomeprazole formulation 2
Number of subjects: 20
Study: 18801669

Group type: EXPERIMENTAL
Intervention: Mixture of autogenous bone and BioOss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture of BioOss and Orthoblast II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BioOss only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic bone, Osteon only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture of allogeneic and xenogeneic bone
Number of subjects: 0
Study: 17076453

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Zaleplon (10 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 15648985

Group type: EXPERIMENTAL
Intervention: Diclofenac 25 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diclofenac 15 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 120
Study: 11329407

Group type: EXPERIMENTAL
Intervention: 150 mg/day of sustained‐release bupropion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8301105

Group type: EXPERIMENTAL
Intervention: Low-salt diet (less than 50 mmol/day)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Normal-salt diet (not specified)
Number of subjects: 187

Group type: COMPARATOR
Intervention: High-salt diet (greater than 200 mmol/day)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Salt loading (prospective study)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Salt sensitivity
Number of subjects: 187
Study: 3307309

Group type: EXPERIMENTAL
Intervention: Insulin at 40 IU/ml (U40)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Insulin at 100 IU/ml (U100)
Number of subjects: 46
Study: 29461856

Group type: EXPERIMENTAL
Intervention: Centrally assisted collaborative telecare (CACT)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Optimized usual care (OUC)
Number of subjects: 666
Study: 27054798

Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy with native tissue vault suspension
Number of subjects: 180

Group type: COMPARATOR
Intervention: Mesh hysteropexy suspension
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 180
Study: 26271057

Group type: EXPERIMENTAL
Intervention: Control of 6 risk factors (no smoking, non-HDL cholesterol <130 mg/dl, triglycerides <150 mg/dl, blood pressure systolic <130 mm Hg; diastolic <80 mm Hg, glycosylated hemoglobin <7%)
Number of subjects: 2265

Group type: COMPARATOR
Intervention: Control of 0 to 2 risk factors during follow-up
Number of subjects: 2265

Group type: EXPERIMENTAL
Intervention: Control of 6 risk factors during follow-up
Number of subjects: 2265
Study: 23675549

Group type: EXPERIMENTAL
Intervention: Coadministered treatment (ivermectin/albendazole/azithromycin)
Number of subjects: 3011

Group type: COMPARATOR
Intervention: Standard therapy (ivermectin/albendazole with azithromycin 1 week later)
Number of subjects: 3011
Study: 20653804

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including toileting assistance, exercise, and choice of food and fluid snacks every 2 hours for 8 hours per day over 3 months
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Anorectal assessments on a subset of 29 residents
Number of subjects: 112
Study: 17661038

Group type: EXPERIMENTAL
Intervention: Glufosfamide 4,500 mg/m(2) + Gemcitabine 1,000 mg/m(2)
Number of subjects: 19
Study: 16768197

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 12936918

Group type: EXPERIMENTAL
Intervention: Dietary fish oil (0.3, 1, and 2 g eicosapentaenoic acid plus docosahexaenoic acid/d for 4 consecutive weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Antioxidant cosupplementation (200 microg Se, 3 mg Mn, 30 mg RRR‐alpha‐tocopheryl succinate, 90 mg ascorbic acid, 450 microg vitamin A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10795943

Group type: EXPERIMENTAL
Intervention: DWI Education
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Coping Skills
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Interactional
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 246
Study: 9106811

Group type: EXPERIMENTAL
Intervention: Intravenous sodium amytal (SA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sympathetic blocks and A-fibre ischemic blocks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Spinal stimulation
Number of subjects: 17
Study: 8441761

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 33
Study: 3763944

Group type: EXPERIMENTAL
Intervention: BN 52063 (PAF antagonist) at a dose of 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BN 52063 (PAF antagonist) at doses of 20, 40, 80, and 120 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29735455

Group type: EXPERIMENTAL
Intervention: 1 mL of 0.2% ropivacaine injection at acupoints Hegu and Sanyinjiao
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline injection at acupoints Hegu and Sanyinjiao
Number of subjects: 120
Study: 28393815

Group type: EXPERIMENTAL
Intervention: Centric stabilization splint (CSS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Soft splint (SS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional anterior repositioning appliance (ARA)
Number of subjects: 30
Study: 24164308

Group type: EXPERIMENTAL
Intervention: UVA1 treatment (medium-dose, four times weekly for 3 months)
Number of subjects: 10
Study: 21785863

Group type: EXPERIMENTAL
Intervention: Single dose of 50 mg/kg clofibrate and phototherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phototherapy alone
Number of subjects: 60
Study: 20090398

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 150
Study: 18773732

Group type: EXPERIMENTAL
Intervention: Images with high Fourier amplitude at spatial frequencies within two octaves of 3 cycles deg(‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Complex images with altered phase or amplitude spectra
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Art images that have received negative public reaction
Number of subjects: 6
Study: 15634716

Group type: EXPERIMENTAL
Intervention: NETE 200 mg plus TU 1000 mg every 8 wk
Number of subjects: 50

Group type: COMPARATOR
Intervention: NETE 200 mg plus TU 1000 mg every 12 wk
Number of subjects: 50

Group type: COMPARATOR
Intervention: TU 1000 mg plus placebo every 12 wk
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus placebo every 6 wk for 12 wk and then every 12 wk
Number of subjects: 50
Study: 12783372

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1106

Group type: COMPARATOR
Intervention: IFN/LDAC
Number of subjects: 1106
Study: 10655919

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 24
Study: 8889345

Group type: EXPERIMENTAL
Intervention: Epoprostenol (Flolan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic assessment
Number of subjects: 0
Study: 1400881

Group type: EXPERIMENTAL
Intervention: GHRP 1 microgram/kg body weight
Number of subjects: 5

Group type: COMPARATOR
Intervention: GHRH 1 microgram/kg body weight
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline (sal)
Number of subjects: 5
Study: 4073878

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride at 0.5 g every 6 h or doxycycline at 100 mg every 12 h for 30 days plus 1 g of streptomycin a day for 21 days (Group A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Rifampin at 15 mg/kg per day in a single morning dose plus 100 mg of doxycycline every 12 h for 30 days (Group B)
Number of subjects: 46
Study: 31737351

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) delivered in 2 face-to-face sessions and 4 phone sessions
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 65
Study: 29485323

Group type: EXPERIMENTAL
Intervention: Multi-ingredient dietary preworkout supplement
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 26659069

Group type: EXPERIMENTAL
Intervention: TDF-FTC
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non-TDF-FTC
Number of subjects: 160
Study: 25283252

Group type: EXPERIMENTAL
Intervention: 3 g/day of oral collagen peptide (CP) for 4 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no collagen peptide)
Number of subjects: 8
Study: 22484523

Group type: EXPERIMENTAL
Intervention: 300 mL of alcohol-free wine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low phenolic diet (LPD)
Number of subjects: 0
Study: 20418184

Group type: EXPERIMENTAL
Intervention: Raw ginger (2 grams for 11 days)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Heat-treated ginger (2 grams for 11 days)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 17823302

Group type: EXPERIMENTAL
Intervention: Walking interval training on treadmill with 40% body weight unloading (BWU) for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 22
Study: 15949594

Group type: EXPERIMENTAL
Intervention: PVU group (2 courses of cisplatin 80 mg/m2, i.v. x 1 (day 1), vindesine 3 mg/m2, i.v. x 1 (days 1 and 8) and UFT 400 mg/day, p.o. for 2 years)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: UFT group (UFT 400 mg/day, p.o. for 2 years)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PVU group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 12446366

Group type: EXPERIMENTAL
Intervention: Increased erythrocyte aldose reductase (AR) levels in NIDDM patients with diabetes duration of less than 10 years
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Increased erythrocyte aldose reductase (AR) levels in NIDDM patients with diabetes duration of 10-20 years
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Increased erythrocyte aldose reductase (AR) levels in NIDDM patients with diabetes duration of 20 years or more
Number of subjects: 611
Study: 10354259

Group type: EXPERIMENTAL
Intervention: Two workshops on physical activity counseling
Number of subjects: 48

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 48
Study: 8526170

Group type: EXPERIMENTAL
Intervention: Artemisia extract
Number of subjects: 25

Group type: COMPARATOR
Intervention: Betula or Phleum extracts
Number of subjects: 25
Study: 1951004

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6613461

Group type: EXPERIMENTAL
Intervention: neurolept anaesthesia combined with thoracic epidural analgesia
Number of subjects: 45

Group type: COMPARATOR
Intervention: neurolept anaesthesia
Number of subjects: 45
Study: 31829286

Group type: EXPERIMENTAL
Intervention: Use of a Fitbit-compatible web app, group education, individual counselling by a physiotherapist, and six phone calls with a physiotherapist.
Number of subjects: 134

Group type: COMPARATOR
Intervention: Delayed control group (6 months later).
Number of subjects: 134
Study: 29576395

Group type: EXPERIMENTAL
Intervention: Transparent chlorhexidine-impregnated dressing with skin-protective acrylic terpolymer barrier film (3M™ Cavilon™ No - Sting Barrier Film)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard transparent catheter dressings without the skin-protecting barrier film
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 60
Study: 27524522

Group type: EXPERIMENTAL
Intervention: Density gradient method
Number of subjects: 220

Group type: COMPARATOR
Intervention: Swim-up method
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 220
Study: 24672814

Group type: EXPERIMENTAL
Intervention: Carvedilol plus NAC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 0
Study: 22135319

Group type: EXPERIMENTAL
Intervention: Atrial Preference Pacing (APP) ON
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atrial Preference Pacing (APP) OFF
Number of subjects: 40
Study: 19841931

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham IMT placebo control
Number of subjects: 16
Study: 17272966

Group type: EXPERIMENTAL
Intervention: CHF 1512
Number of subjects: 74

Group type: COMPARATOR
Intervention: LD/CD
Number of subjects: 74
Study: 15599128

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions
Number of subjects: 171
Study: 12172327

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 10458542

Group type: EXPERIMENTAL
Intervention: Lentinan (2 mg) administered 7 days before surgery
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (15 patients)
Number of subjects: 25
Study: 7791055

Group type: EXPERIMENTAL
Intervention: Topical ketorolac (Acular)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Topical diclofenac (Voltaren)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control medication (HypoTears)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen #3
Number of subjects: 140
Study: 2225696

Group type: EXPERIMENTAL
Intervention: Acetaminophen (2.7 gm/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8